Directorate Change

RNS Number : 6049J

Venn Life Sciences Holdings PLC

13 September 2016

 

Venn Life Sciences Holdings Plc

("Venn Life Sciences" or the "Company" or the "Group")

Appointment of Chairman

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Allan Wood as Chairman to the Board with effect from 20 September 2016 taking over from Tony Richardson who has been acting as Executive Chairman since January 2016.

Allan Leigh Wood, aged 52, was previously Managing Director of Xansa Plc, an outsourcer of business processing solutions. Since then he has held a number of positions as a Non-Executive Director and Chairman of multiple companies across a broad range of fields where he has acquired skills that will  benefit Venn.

Tony Richardson, Chief Executive Officer of Venn said: "I am delighted to welcome Allan to Venn. Allan has extensive relevant experience in scaling businesses in health services and related sectors and I believe will add significant value as we seek to continue our current growth trajectory. Allan's experience includes both organic business growth and M&A and together we can continue to build a successful and sustainable business for shareholders."

Mr. Wood has confirmed that there are no other items requiring disclosure in accordance with Schedule 2(g)(iii) to (viii) of the AIM Rules and the ESM Rules.

Current directorships or partnerships	Directorships or partnerships in the last five years
Oxehealth Limited	Trustmarque Solutions Limited
Ardvarna Investment Capital Limited	Healthcare Homes Holdings Limited
Eclipse Film Partnership No. 22 LLP	HWH Plus Limited
The Augusta Film Limited Liability Partnership	HWH Group Limited
	WCI Group Trustee Company Limited
	Creare Franchise Limited
	Creare Communications (UK) Limited
	Creare Communications (Holdings) Limited
	Care UK (Urgent Care) Holdings Limited

Mr. Wood does not hold any ordinary shares in Venn Life Sciences.

Venn Life Sciences Holdings Plc		www.vennlifesciences.com
Tony Richardson, Chief Executive Officer		Tel: [phone]
Davy (Nominated Adviser, ESM Adviser and Joint Broker)
Fergal Meegan / Matthew de Vere White (Corporate Finance)		Tel: [phone]
Paul Burke (Corporate Broking)
Hybridan LLP (Co-Broker)
Claire Louise Noyce		Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus		Mob: [phone]

About Venn Life Sciences: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

 

END

 

 

BOABUGDCUDBBGLD